Published online Mar 27, 2016. doi: 10.5313/wja.v5.i1.1
Peer-review started: April 9, 2015
First decision: September 2, 2015
Revised: November 14, 2015
Accepted: December 4, 2015
Article in press: December 8, 2015
Published online: March 27, 2016
Processing time: 352 Days and 4 Hours
Gastrointestinal endoscopy is the gold standard in the examination and the treatment of the diseases of gastrointestinal system, but the disadvantage of being painful process. At this point the sedative and analgesic agents may be important. Dexmedetomidine is a new sedoanalgesic agent which is alternative to benzodiazepines and opioids. It has analgesia, amnesia, sedative and anxiolytic properties. The use of dexmedetomidine as the sole anesthetic agent and as the adjuvant analgesic agent has been published but has not been approved because of the inconsistency of efficacy and safety. The author has been collected the published papers in the literature. This article is aimed to describe the use of dexmedetomidine in various gastrointestinal endoscopic procedures.
Core tip: Dexmedetomidine has analgesic, amnesic, sedative and anxiolytic properties. Use of dexmedetomidine as the sole anesthetic agent and as the adjuvant anesthetic agent in various gastrointestinal endoscopic (GIE) procedures has been published. A distinct advantage of dexmedetomidine is the maintenance of respiratory force and preserved airway patency. These properties of dexmedetomidine have verified to be beneficial in high-risk patients. This article is aimed to explain the clinical use of dexmedetomidine for GIE procedures of the published papers in the literature.